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Research
AbstrACt
Objectives To investigate patterns of industry-sponsored 
educational events that focus on specific health conditions 
for which there are concerns about overdiagnosis and 
overtreatment.
Design and setting This retrospective cohort study 
examines publicly reported industry-sponsored events 
in Australia from October 2011 to September 2015 for 
three conditions potentially subject to overdiagnosis and 
overtreatment: depression, osteoporosis and overactive 
bladder. We used a database of transparency reports to 
identify events with a focus on depression, osteoporosis 
and overactive bladder and compared these with other 
sponsored events. We hypothesised that companies 
marketing treatments for each condition would sponsor 
related events and that target audiences would mainly 
work in primary care, reflecting a broad patient population.
Main outcome measures Event and attendee 
characteristics, sponsoring companies, related marketed 
treatments, cost-effectiveness ratings and dispensing 
rates.
results Over the study period, we identified 1567 events 
focusing on depression, 1375 on osteoporosis and 190 on 
overactive bladder (total n=3132, with 96 660 attendees). 
These events were attended by primary care doctors more 
often than sponsored events without a focus on these 
three conditions: relative risk (RR)=3.06 (95% CI 2.81 
to 3.32) for depression, RR=1.48 (95% CI 1.41 to 1.55) 
for osteoporosis and RR=2.59 (95% CI 2.09 to 3.21) for 
overactive bladder. Servier, which markets agomelatine 
and AstraZeneca (quetiapine) sponsored 51.2% and 
23.0% of depression events, respectively. Amgen 
and GlaxoSmithKline, which co-market denosumab, 
sponsored 49.5% of osteoporosis events and Astellas and 
Commonwealth Serum Laboratories (CSL) (mirabegron and 
solifenacin) sponsored 80.5% of overactive bladder events.
Conclusions This 4-year overview of industry-sponsored 
events on three overdiagnosed and overtreated conditions 
found that primary care clinicians were often targeted, 
dinner was often provided and that a few companies 
sponsored most events. In most cases, sponsors’ products 
are not cost-effective choices for the specified condition. 
This pattern highlights the need for professional education 
to be free of commercial sponsorship.
IntrODuCtIOn 
The role of pharmaceutical industry spon-
sorship of health professional education has 
been subject to considerable controversy. 
There is disagreement about whether spon-
sored education is primarily promotional or 
educational. It has been described on the one 
hand as ‘marketing masquerading as educa-
tion’1 and on the other, if accompanied by 
proper controls, as able to meet the goal of 
‘needs based, relevant, accessible education 
that is balanced and unbiased and improves 
healthcare outcomes.’2 
This controversy extends to how treatment 
outcomes are discussed and how condi-
tions are defined. Messages in commer-
cially sponsored education may exaggerate 
prevalence and/or attempt to medicalise 
strengths and limitations of this study
 ► Australia’s transparency reports of industry funding 
of health professionals were unique internationally 
until 2015, in that the focus was on sponsored 
events.
 ► This is the first data-driven national analysis of 
condition-specific industry educational event 
sponsorship for overdiagnosed and overtreated 
conditions.
 ► Classification of events was blinded to sponsor, 
attendee characteristics and event descriptions.
 ► For each condition, we examined trends over time 
in sales and dispensing of lead sponsors’ relevant 
marketed drugs, but we could not assess causal 
links between increased prescribing and event 
attendance, as no information was publicly available 
on the identity of individual event participants.
 ► Limited detail was available on the content of 
sponsored events; therefore, despite a sensitive 
search, we may have missed some relevant events 
per condition.
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aspects of ordinary life. Identified ‘marketing messages’ 
in continuing medical education (CME) for low female 
sexual desire included statements that it is ‘very common 
and underdiagnosed’ and that ‘women may not be aware 
that they are sick or distressed.’3 Similarly, US CME 
sponsored by a testosterone manufacturer supported a 
broader definition of hypogonadism than in listed indica-
tions for testosterone.4
A sponsored CME campaign can reach many health 
professionals, with potential widespread effects on prac-
tice. Purdue Pharma’s launch of the opioid analgesic 
oxycodone in the USA included over 20 000 sponsored 
educational events, many of which targeted general prac-
titioners (GPs), potentially contributing to more opioid 
use in primary care.5
These are product-specific examples of sponsored 
CME that received media attention and may not reflect 
broader trends. There has been little exploration of the 
link between sponsored CME and specific conditions 
prone to overdiagnosis. Overdiagnosis, the detection of 
conditions unlikely to lead to ill health, disability or death 
in the absence of treatment, has been characterised as a 
‘modern epidemic’.6 7 It can lead to harm from adverse 
effects of treatments from which a person is unlikely to 
benefit, to psychological harm if a healthy person suffers 
from anxiety or stigma due to disease labelling and to 
harm to society through higher healthcare costs. There 
is evidence of commercial influence on overdiagnosis 
in a range of conditions through direct and indirect 
marketing aiming to establish the need for a product.7 
One consequence of overdiagnosis is overtreatment, as 
overdiagnosis expands the pool of potentially treatable 
patients beyond thresholds at which treatment has been 
shown to be beneficial. The wide ranging influence of 
industries that benefit from expanded markets has been 
highlighted as a key driver.8
National patterns of industry sponsorship can shed 
light on controversies concerning the role of sponsored 
CME. From 2007 to late 2015, members of Medicines 
Australia, the national pharmaceutical industry trade 
association, were required by law to report on sponsored 
events for health professionals.9 These are described by 
Medicines Australia as ‘educational events’ and include 
both accredited CME and a large range of events without 
accreditation.10
Australia was one of the first countries to require the 
pharmaceutical industry to publicly report financing 
of hospitality for health professionals. In 2007, the 
Australian Competition Tribunal required Medicines 
Australia—who at the time opposed the move—to intro-
duce mandatory disclosure of industry-sponsored events 
for health professionals following recommendations 
by the Australian Competition and Consumer Commis-
sion (ACCC). Unlike other countries relying on industry 
self-regulation of drug promotion via national industry 
associations, Australia has what could be described as a 
quasi-regulatory system, requiring approval of self-regu-
latory standards by a public regulatory body, the ACCC.11
These data provide a unique opportunity to examine 
the link between condition-specific sponsored events and 
companies marketing medicines for a condition. Over 
this 4-year period, 116 845 events are described, varying 
in scope from a half-hour journal club in a hospital 
meeting room to several-day conferences, sometimes 
held overseas.12
We report here on event sponsorship with a focus on 
three conditions highlighted in the medical literature as 
potentially subject to overdiagnosis and overtreatment: 
depression,13 osteoporosis14 and overactive bladder.15 We 
hypothesise that companies marketing drugs for these 
conditions are more likely to sponsor events with a focus 
on that condition than other companies. We also hypoth-
esise that these events tend to target primary care practi-
tioners who are likely to treat milder disease states than 
specialists. To test these hypotheses, we compare charac-
teristics of the events focusing on these three conditions 
with other events sponsored by companies during the 
4-year study period.
To investigate clinical implications, we examine whether 
sponsors’ products were judged to be cost-effective and 
are covered under Australia’s Pharmaceutical Bene-
fits Schemes (PBS). The PBS was introduced in 1948 to 
subsidise the costs of outpatient medicines for the entire 
Australian population. The aim is to provide affordable 
access to needed medicines. An expert committee, the 
Pharmaceutical Benefits Advisory Committee (PBAC), 
recommends listing of medicines based on cost-effective-
ness considerations that include both therapeutic gains 
and price. Medicines not listed on the PBS tend to have 
very limited sales.
We assess sponsorship patterns per condition in terms 
of audience, clinical versus non-clinical setting and provi-
sion of meals. We examine how often events included 
company-sponsored dinners as events with dinners 
provided are often held at restaurants and represent a 
higher value gift. For products for which there was a shift 
in which company held distribution rights over the study 
period, we also examine timing of event sponsorship in 
relation to distribution rights.
MethODs
Data sources
We downloaded 301 publicly available company reports 
covering the period from October 2011 to September 
2015 from the Medicines Australia website (www. medi-
cinesaustralia. com. au), converted them from PDF into 
Excel files, cleaned the data and resolved discrepancies. 
For example, we removed text from columns that should 
have contained numeric values only (eg, total cost) and, 
for a small minority of events, corrected totals equal to 
less than reported component costs.
These reports include the sponsoring company, timing, 
event description, venue type, number and profession 
of attendees, hospitality costs and total event costs. 
Coding methods are described in detail elsewhere.12 We 
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developed a retrospective cohort of sponsored events 
based on timing of sponsorship per company over time. 
A descriptive overview of the data on sponsored events 
has been published,12 and the dataset used for this 
analysis is available at http:// dx. doi. org/ 10. 4227/ 11/ 
592631edbd9d5.
We obtained a list of brands sold in Australia for each 
condition from the Australian Medicines Handbook16 and 
manufacturers’ websites and annual dispensing data 
for publicly reimbursed drugs through Australia’s PBS 
at http://www. pbs. gov. au/ info/ browse/ statistics# AS. 
For non PBS-subsidised drugs, sales volume data were 
obtained through Quintiles IMS.
We examined volume of use using annual numbers 
of dispensed prescriptions for PBS-subsidised drugs and 
numbers of units sold to retail and hospital pharmacies 
for non PBS-subsidised drugs.
selection of targeted conditions
We chose depression, osteoporosis and overactive bladder 
as illustrative case studies of conditions for which diag-
nostic thresholds and treatment have extended beyond 
levels at which patients are likely to benefit. We selected 
these conditions a priori before carrying out any analyses.
Depression screening leads to many false positives,17 18 
and many patients prescribed antidepressants in primary 
care fail to meet diagnostic criteria for major depression,19 
a phenomenon that has been described as ‘medicalising 
sadness’.13 In 2013, Australia had one of the highest rates 
of antidepressant use among Organisation for Economic 
Cooperation and Development (OECD) countries.20
Questions have also been raised about diagnostic 
criteria for osteoporosis and the role of bone densi-
tometry in greatly expanding the treatable population, 
primarily when used in screening of asymptomatic post-
menopausal women and as a diagnostic tool for women 
with low-trauma fractures. Bone density screening is 
poorly predictive of clinical fractures, and a focus on 
bone density rather than fragility fractures has led to 
many more diagnoses.14 Further treatment expansion 
has occurred through lowered thresholds for ‘pre-osteo-
porosis’ and ‘osteopenia’, which further extend disease 
labelling to populations that fail to meet established 
criteria for a diagnosis of osteoporosis.
An ‘imprecise’ symptom-based definition of over-
active bladder, largely linked to commercial interests, 
has replaced urodynamically confirmed bladder insta-
bility.15 Tolterodine, marketed by Pharmacia, was the 
first drug approved for overactive bladder symptoms. In 
2002, Pharmacia’s vice president described a threefold 
expansion of the treatable population through a defini-
tion of overactive bladder no longer requiring urinary 
incontinence.21
Drug treatments for these three conditions have been 
heavily advertised to the public in the USA, with adver-
tising that relies heavily on emotional appeals, targets 
women and tends to blur the boundaries between normal 
life and medical conditions requiring treatment.22
Coding of Medicines Australia data on sponsored events
An initial coding scheme for industry-sponsored events 
included sponsoring company, location, attendee profes-
sion, clinical focus, type of hospitality (such as whether 
meals or travel and accommodation were provided) and 
a set of relevant keywords to search unstructured text.12 
We designed an additional coding scheme to identify 
events focusing on the three included conditions. The 
research team iteratively developed keywords based on 
disease names/symptoms and drug classes and products 
sold in Australia (generic and brand names) for each 
condition. Keywords were used to search unstructured 
text in the ‘Description of function’ column of reports. 
All relevant keywords associated with one or more events 
listed in the database were retained in the final coding 
scheme (see online supplementary appendix tables 1 and 
2). During coding, we concealed other variables (using 
Excel’s ‘Column Hide’ function) to blind the coder (SS) 
to sponsor, attendee characteristics and event descriptors.
Analysis
For each included condition, we provide a detailed anal-
ysis for all companies sponsoring at least 5% of events. 
We examined whether these companies market drugs to 
treat the condition and PBS reimbursement status for 
these drugs. We present frequency tables for event and 
attendee characteristics. Costs are reported in Australian 
dollars. We performed χ2 analyses to compare events per 
condition with other sponsored events using SPSS V.22.
results
Over the 4-year study period, we identified 3132 events 
focusing on the three conditions, with 96 620 attendees. 
This included 1567 events with a focus on depression, 
with 41 474 attendees; 1375 on osteoporosis with 33 916 
attendees and 190 on overactive bladder with 21 270 
attendees. As no individuals are named, we could not 
ascertain numbers of repeat attendees. Table 1 summarises 
event characteristics. Events focusing on these conditions 
represent 2.7% of sponsored events (n=116 845) over the 
4-year period and 2.8% of attendees (n=3 481 750).12
For all three conditions, the median number of event 
attendees (19 to 20) was similar to sponsored events 
in general.12 For all three conditions, events were held 
less often in a clinical setting (hospital or clinic) than 
other sponsored events: relative risk (RR)=0.51 (95% 
CI 0.50 to 0.53) for depression; RR=0.72 (95% CI 0.68 
to 0.76) for osteoporosis; RR=0.47 (95% CI 0.43 to 
0.50) for overactive bladder. Nurses were only at 24.4% 
of condition-focused events compared with 39.6% of 
total events,12 likely reflecting the less frequent hospital 
setting. However, attendees were more likely to be 
primary care physicians (GPs or family medicine) than 
at other events: RR=3.06 (95% CI 2.81 to 3.32) for 
depression, RR=1.48 (95% CI 1.41 to 1.55) for osteo-
porosis, and RR=2.59 (95% CI 2.09 to 3.21) for overac-
tive bladder. Depression and osteoporosis events were 
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also more likely to feature a dinner than other events: 
RR=1.73 (95% CI 1.64 to 1.82) for depression and 
RR=1.33 (95% CI 1.27 to 1.38) for osteoporosis. This 
trend was not seen for overactive bladder.
The median cost per attendee was higher than for 
events in general ($A14): $A104 for depression, $A52 for 
osteoporosis and $A85 for overactive bladder (table 1).
A few companies sponsored most of these condi-
tion-focused events. Figure 1 provides an overview of 
companies sponsoring ≥5% of events. All sell at least 
one drug for the relevant indication. Table 2 provides 
an overview of these drugs’ PBS funding status. We 
present illustrative event descriptions featuring brand 
names in table 3, with added details on sponsored 
events per company in online supplementary appendix 
table 3.
Depression-related events
Two companies sponsored >80% of depression-related 
events: Servier (51.2% of events), which markets the 
antidepressant agomelatine and AstraZeneca (23.0% of 
events), which markets the antipsychotic quetiapine. The 
extended-release formulation of quetiapine (brand name 
Seroquel XR) is approved for depression treatment in 
patients intolerant to other therapies or with inadequate 
response. Neither agomelatine nor the depression indi-
cation for quetiapine are PBS subsidised. Pfizer, which 
markets five PBS-subsidised antidepressants (desvenla-
faxine, venlafaxine, sertraline, reboxetine, doxepin), was 
the next most frequent sponsor (16.0% of events).
We examined agomelatine and quetiapine sales 
volumes over the study period. Agomelatine sales tripled, 
from 99 625 units in 2012 to 300 103 units in 2015 (28 days 
treatment/unit). Sales of the extended-release formula-
tion of quetiapine increased from 247 374 units in 2012 to 
374 917 in 2015 (60 days treatment/unit). Sales of other 
AstraZeneca quetiapine formulations decreased over the 
same period, from 499 445 units sold in 2012 to 202 783 in 
201523 (see online supplementary appendix figure 1.1).
Figure 1 Per cent of events sponsored by each company, in total and per condition. Companies that sponsored at least 5% of 
events are listed. 
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Seventy-nine AstraZeneca events focused on ‘the 
anxious depressed patient’. Figure 2 is an invitation for 
one of these events, featuring the same image that was 
used in an advertisement for extended-release quetiapine 
that appeared in the Medical Journal of Australia. This 
formulation of quetiapine is also indicated for gener-
alised anxiety disorder.
Osteoporosis-related events
Osteoporosis event sponsorship, similarly, was highly 
concentrated: Amgen and GSK, which comarket denos-
umab, sponsored 31.3% and 18.1% of events respectively 
(in total, 49.4%). Novartis, which markets zoledronic 
acid, and oestradiol/norethisterone, a hormone therapy 
approved for osteoporosis prevention in high-risk women 
intolerant of other products, sponsored 19.9% of events; 
Servier, which markets strontium, sponsored 15.0%; and 
Sanofi, which marketed risedronic acid until December 
2014, sponsored 8.7%. Denosumab, zoledronic acid, 
oestradiol/norethisterone and risedronic acid are PBS 
subsidised; strontium was delisted in August 2016 due to 
cardiac risks.
Sanofi transferred its marketing rights for risedro-
nate to Actavis in December 2014.24 Sanofi sponsored 
no osteoporosis events from October 2014 onwards (see 
online supplementary appendix figure 1.2).
Denosumab dispensations increased nearly sevenfold 
over the study period, from 45 220 in 2012 to 309 350 
in 2015.25 Risedronate, zoledronic acid and strontium 
dispensations all decreased (see online supplementary 
appendix figure 1.3) Of 193 events mentioning denosum-
ab’s brand name, Prolia, 104 were sponsored by Amgen 
and 88 by GSK.
Overactive bladder-related events
Two companies dominated sponsorship of overactive 
bladder events: Astellas (40.5% of events), which markets 
mirabegron and solifenacin, the latter after October 2014 
and CSL (40.0% of events), which marketed solifenacin 
from February 2011 to October 2014. Neither drug is 
PBS subsidised. Astellas did not request PBS reimburse-
ment for mirabegron. PBAC rejected solifenacin in 2007, 
judging benefits and cost-effectiveness to be uncertain.
All CSL-sponsored overactive bladder events occurred 
while the company held distribution rights for solifenacin 
to October 2014. Most Astellas-sponsored events were 
held from 2014 onwards, when it obtained marketing 
rights (see online supplementary appendix figure 1.4). 
Figure 2 Invitation for an AstraZeneca sponsored event.
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Both solifenacin and mirabegron sales increased over the 
study period (see online supplementary appendix figure 
1.5).
DIsCussIOn
In this analysis of 3132 Australian pharmaceutical indus-
try-sponsored events with 96 660 attendees, focusing on 
three clinical conditions prone to overdiagnosis, we found 
a strong concentration of sponsorship among few compa-
nies. Two companies sponsored over 70% of depression 
events; another two companies over 80% of overactive 
bladder events. For osteoporosis, the two companies that 
comarket denosumab sponsored nearly 50% of events.
Several products marketed by key event sponsors were 
considered unacceptable for PBS reimbursement, and 
are associated with cost, efficacy and safety concerns that 
have been flagged internationally. Servier, which spon-
sored over half of depression-related events, sells agome-
latine which is not PBS subsidised. Agomelatine is not 
approved in the USA or Canada. A French independent 
drug bulletin, Prescrire, characterised the drug as ‘more 
dangerous than useful’ and called for its withdrawal in 
2015.26 A Spanish bulletin, similarly, considered it ‘worse 
than first-line antidepressants, up to 15-fold more expen-
sive and a worrying hepatic safety profile.’27
A 2012 Cochrane systematic review found that Astra-
Zeneca’s atypical antipsychotic quetiapine had limited 
efficacy evidence for depression.28 An updated systematic 
review, published in 2015, concluded that quetiapine had 
not been shown to improve function and that method-
ological biases had exaggerated benefits and minimised 
harm.29
Like agomelatine, denosumab is on the French bulletin 
Prescrire’s list of 71 drugs to avoid in 2016 because of ‘a 
disproportionate risk of adverse events’ including serious 
infections due to immunosuppression, with only modest 
efficacy.30 In 2015, half of all new Australian osteoporosis 
prescriptions were for denosumab.31
All anticholinergic overactive bladder drugs, including 
solifenacin, have modest benefits, preventing one incon-
tinence episode on average every 2 days, with frequent 
dry mouth and constipation, and there is observational 
evidence of dementia risk with longer term use.32 Mira-
begron has similar efficacy to anticholinergics32 and can 
lead to severe hypertension.33
This analysis is limited by the data available. Our anal-
ysis only includes 2.7% of events, a likely underestimate 
as not all event descriptions mention a condition. These 
three conditions are illustrative case studies and cannot 
be assumed to represent all condition-related sponsored 
events. A variety of influences are expected to affect sales 
trends, including a large range of promotional activities. 
Sponsored events represent only one aspect of broader 
promotional campaigns to promote sales.34 However, 
a strength of this analysis is that it covers all sponsored 
events in Australia over 4 years, and coding was blinded to 
sponsor identity, types of attendees, gifts and costs. Due 
to the unique Australian dataset, this is the first such data-
driven national analysis to examine condition-specific 
event sponsorship.
Company reports on financing of sponsored events 
provided limited information on content, leaving many 
questions unanswered. More research is needed on the 
messages in sponsored education, including on thresh-
olds for disease diagnosis and treatment. Additionally, as 
individuals were not named, we could not directly eval-
uate the link between event attendance and individual 
prescribing patterns.
We could only examine potential contributions to 
overdiagnosis and overtreatment indirectly. We had 
hypothesised that events would focus on primary care, 
reflecting milder disease states. This is a hypothesised 
association only; we could not directly assess whether 
the messages in these events promote overdiagnosis or 
overtreatment. However, nearly two-thirds of events, 
62%, for the three conditions were attended by primary 
care doctors, versus 21% of other events. The focus 
on primary care was most pronounced for depression 
events: 74%.
The concentration of sponsorship by companies 
marketing products subject to safety, cost and efficacy 
concerns raises questions about influences on prescribing 
choice. This pattern is consistent with Brody and Light’s 
hypothesis of an ‘inverse benefit law’, in which intense 
marketing of drugs that may benefit a small proportion 
of patients is harmful to public health because a broader 
patient population is targeted than is likely to benefit.35
Many of these condition-focused events included 
dinner and were held in non-clinical settings such as 
restaurants. Costs per person were higher than for events 
in general. Even small gifts, such as food and drink, 
can affect behaviour.36 An analysis of US transparency 
reports found that physicians who receive one or more 
sponsored meals with a mean value of <US$20 were more 
likely to prescribe the promoted product, with larger 
effects observed the more meals received.37 We exam-
ined whether overseas travel may have been responsible 
for higher median costs. In total (n=1 17 845), 1.9% of 
events were held overseas, and as expected, these events 
had the highest per person costs. However, only 0.1% of 
depression-related events, 0.4% of osteoporosis-related 
events and no overactive bladder events were held over-
seas. Therefore, this is an unlikely explanation. Travel 
costs within Australia are not reported separately from 
other hospitality costs, so we could not examine their 
contribution to overall costs.
Timing of sponsorship was linked to when a company 
sold a drug to treat the included condition, consistent 
with a sales orientation. Companies discontinued event 
sponsorship of overactive bladder and osteoporosis events 
when they no longer had marketing rights for a product 
for these conditions. This promotional orientation is 
consistent with internal documents released during the 
US legal case on gabapentin, which described the use of 
CME to market off-label use.38
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In this 4-year overview of industry-sponsored events 
focusing on depression, osteoporosis and overactive 
bladder, we found concentrated sponsorship among 
few companies per condition. These companies mainly 
market products that are not considered cost-effec-
tive choices for the specified conditions. This raises 
concerns about impacts on prescribing quality and on 
national prescribing trends. There was a strong focus on 
primary care physicians, frequent provision of dinner 
and non-clinical settings. Although a focus on primary 
care does not necessarily imply promotion of overdiag-
nosis, promotion in primary care is consistent with a 
focus on a broader rather than narrower patient popu-
lation. This observed pattern of event sponsorship raises 
concerns about the role of industry-sponsored educa-
tion in conditions identified as prone to overdiagnosis 
and highlights the need to ensure that professionals 
have ready access to continuing professional education 
that is free of commercial sponsorship.
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